NRx says FDA reviewers have raised no major issues with its preservative-free ketamine ANDA, as the company prepares for a potential third-quarter decision and continues manufacturing and financing work ahead of launch.
Dean Rudge
Geo Focus
Coverage Attributes:
Beta
Informative:
59
%
Promotional:
17
%
Opinion:
7
%
Reviews:
5
%
Interviews Q&as:
4
%
Themes Covered:
Not enough data
Pitching Insights
Dean Rudge's coverage predominantly focuses on the healthcare and pharmaceutical industry, with a specific emphasis on pharmaceutical companies, biosimilars, drug market dynamics, and patent issues. His articles mainly provide announcements from the private sector within this industry.
Given his focus on private sector announcements and press releases in the pharmaceutical space, Dean may be particularly interested in pitches that offer exclusive insights or interviews with key figures at pharmaceutical companies regarding new product launches, legal battles over patents or biosimilars, or strategic business moves such as acquisitions or market entries.
Considering the scientific themes present in his coverage attributes along with topics covered like biosimilars and drug markets suggest he might also be open to pitches featuring expert commentary from researchers or professionals who can speak to advancements within these areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Managing Editor Europe, Commercial
Publications
Most recent topics
Not enough data
Healthcare Reporter
Publications
Most recent topics
Not enough data
